Cargando…

Pan-immune-inflammation and its dynamics: predictors of survival and immune-related adverse events in patients with advanced NSCLC receiving immunotherapy

OBJECTIVES: Pan-immune-inflammation value (PIV) is defined by the neutrophil, platelet, monocyte, and lymphocyte counts and is associated with immune-checkpoint inhibitor (ICI) therapy outcomes in advanced non-small cell lung cancer (aNSCLC). However, PIV is dynamic under therapy and its longitudina...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yiqun, Gong, Lingyan, Gu, Pengyang, Hua, Yiwen, Sun, Yingfang, Ni, Songshi, Zhou, Xiaoyu, Tang, Zhiyuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557237/ https://www.ncbi.nlm.nih.gov/pubmed/37803437 http://dx.doi.org/10.1186/s12885-023-11366-4

Ejemplares similares

Multi‐organs perioperative immune‐related adverse events and postoperative bronchial anastomotic fistula in a patient receiving neoadjuvant immunotherapy with NSCLC
por: Xu, Yuan, et al.
Publicado: (2022)

Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy
por: Jing, Ying, et al.
Publicado: (2022)

Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy
por: He, Xiujing, et al.
Publicado: (2021)

Elevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC)
por: Tang, Zhiyuan, et al.
Publicado: (2016)

Immune‐related adverse events and outcomes among pan‐cancer patients receiving immune checkpoint inhibitors: A monocentric real‐world observational study
por: Ge, Xiaoxiao, et al.
Publicado: (2023)

Clinical Outcomes of Patients With Metastatic NSCLC After Discontinuation of Immunotherapy Because of Immune-Related Adverse Effects
por: Lievense, Lysanne A., et al.
Publicado: (2022)

The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
por: Ke, Wanhai, et al.
Publicado: (2020)

Enhanced monoacylglycerol lipolysis by ABHD6 promotes NSCLC pathogenesis
por: Tang, Zhiyuan, et al.
Publicado: (2020)

Immune-related adverse events and the balancing act of immunotherapy
por: Conroy, Michael, et al.
Publicado: (2022)

Progressive Pleural Effusion as an Immune-Related Adverse Event in NSCLC: A Case Report
por: Shen, Chia-I, et al.
Publicado: (2021)

The Predictive Model Construction for Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy
por: Gao, Weitong, et al.
Publicado: (2023)

38351 Immune-related adverse events in cancer patients receiving immune checkpoint inhibitors
por: Lucas, Margaret Byrnethew, et al.
Publicado: (2021)

Evaluation of autoantibodies as predictors of treatment response and immune‐related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan‐cancer study
por: Barth, Dominik A., et al.
Publicado: (2022)

A model‐based meta‐analysis of immune‐related adverse events during immune checkpoint inhibitors treatment for NSCLC
por: Zhang, Renwei, et al.
Publicado: (2022)

Contribution of upregulated dipeptidyl peptidase 9 (DPP9) in promoting tumoregenicity, metastasis and the prediction of poor prognosis in non‐small cell lung cancer (NSCLC)
por: Tang, Zhiyuan, et al.
Publicado: (2017)

Immune-related Adverse Events in Patients With Cancer Receiving Influenza Vaccination and Immune Checkpoint Inhibitors
por: Groeneveld, Geert H, et al.
Publicado: (2020)

Immune-Related Adverse Events in the Older Adult with Cancer Receiving Immune Checkpoint Inhibitor Therapy
por: Biniakewitz, Matthew D., et al.
Publicado: (2020)

Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management
por: Stucci, Stefania, et al.
Publicado: (2017)

Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy
por: Olsen, T. Anders, et al.
Publicado: (2022)

Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
por: Albarrán-Artahona, Víctor, et al.
Publicado: (2022)

Immune-related adverse events of biological immunotherapies used in COVID-19
por: Baracaldo-Santamaría, Daniela, et al.
Publicado: (2022)

Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy
por: Huang, Xing, et al.
Publicado: (2020)

A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade Immunotherapy
por: Yang, Jing, et al.
Publicado: (2022)

Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy
por: Wang, Haowei, et al.
Publicado: (2022)

Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis
por: Zhang, Dongyu, et al.
Publicado: (2021)

Construction and Evaluation of Clinical Prediction Model for Immunotherapy-related Adverse Events and Clinical Benefit in Cancer Patients Receiving Immune Checkpoint Inhibitors Based on Serum Cytokine Levels
por: Zhao, Ni, et al.
Publicado: (2023)

The pan-immune-inflammation value and systemic immune-inflammation index in advanced melanoma patients under immunotherapy
por: Susok, L., et al.
Publicado: (2022)

Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy
por: Jing, Ying, et al.
Publicado: (2020)

T follicular helper cells: linking cancer immunotherapy and immune-related adverse events
por: Baumjohann, Dirk, et al.
Publicado: (2021)

The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer
por: Coschi, Courtney H., et al.
Publicado: (2021)

Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy
por: Bolte, Fabian J., et al.
Publicado: (2022)

Extracellular Vesicle-Derived Protein File from Peripheral Blood Predicts Immune-Related Adverse Events in Gastric Cancer Patients Receiving Immunotherapy
por: Jiang, Fangli, et al.
Publicado: (2022)

Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy
por: Watson, Alexander S., et al.
Publicado: (2022)

Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors
por: Hsiehchen, David, et al.
Publicado: (2019)

Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review
por: Barron, Carly C, et al.
Publicado: (2023)

Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy
por: Van Buren, Inga, et al.
Publicado: (2023)

Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy
por: Zhao, Ni, et al.
Publicado: (2022)

T-cell tolerant fraction as a predictor of immune-related adverse events
por: Ostmeyer, Jared, et al.
Publicado: (2023)

The Immune System’s Echo: The Phenomenon of Delayed Neurological Immune-Related Adverse Events (NirAEs) in Adjuvant Immunotherapy
por: Gohel, Shruti, et al.
Publicado: (2023)

Pan-cancer analysis of TASL: a novel immune infiltration-related biomarker for tumor prognosis and immunotherapy response prediction
por: Li, Huanyu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6mmlg9sa621sek7phkcvbc3q01